up was carried out with quarterly semen analysis and hormonal profiles. Detection of sperm in ejaculate and achievement of pregnancy spontaneously or with assisted reproductive tecniques were the predetermined primary and secondary endpoints.
INTRODUCTION AND OBJECTIVES: One of the recognized effects of standard forms of testosterone (T) therapy is suppression of the pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via negative feedback from sustained increases in serum T concentrations. We report here the results of treatment with a 4.5% testosterone gel administered intranasally (nasal testosterone gel -NTG) on serum total testosterone (TT), LH, and FSH in hypogonadal men.
METHODS: Hypogonadal men were randomized into a 90day, open-label, dose-ranging study. A 4.5% NTG (125 uL/nostril, 11.0mg testosterone/dose) was self-administered using a multipledose dispenser either twice daily (BID, n¼122) or 3 times a day (TID, n¼151) for a total dose of 22.0mg or 33.0mg, respectively. Titration was performed based on blood levels so as to achieve the eugonadal range (300 -1050 ng/dL). Serum samples were obtained at baseline and after 90 days of treatment to determine relevant hormone levels.
RESULTS: Total serum testosterone increased from a mean Cavg 200.8 ng/dL at baseline to a mean Cmax 818.49 ng/dL at~40 minutes. After 90 days, 90% (95% CI ¼ 83-97%) of men in the TID group, and 71% (95% CI ¼ 62-79%) of men in the BID group reached normal T levels, and a mean total testosterone Cavg 421 ng/dL and 375 ng/dL, respectively. Baseline FSH (BID) was 8.49 IU/L, mean at Day 90 was 5.99 IU/L. Baseline FSH (TID) was 6.42 IU/L, mean at Day 90 was 3.12 IU/L. Baseline LH (BID) was 5.42 IU/L, mean at Day 90 was 3.56 IU/L. Baseline LH (TID) was 5.25 IU/L, mean at Day 90 was 2.20 IU/L. CONCLUSIONS: Treatment with 4.5% NTG restored serum TT to normal levels while FSH and LH levels were reduced but remained well within the normal range mitigating the decline in LH and FSH. This maintenance of normal gonadotropins differs from the usual suppression seen with other exogenous T preparations, particularly injections. The mechanism for this reduced gonadotropin suppression is uncertain, but may be due to return of serum T to baseline between doses. Further studies are needed to determine to what extent this reduced gonadotropin suppression may result in preservation of testicular volume and fertility. 
INTRODUCTION AND OBJECTIVES:
Hypogonadotropic hypogonadism is a rare disease for infertile patients. Generally, sperm can be obtained in ejaculate after medical treatment, but some patients can undergo testicular sperm extraction. The aim of the present study was to evaluate ART outcomes in men with hypogonadotropic hypogonadism.
METHODS: A total of 119 ART cycles in 61 patients were evaluated in this study between January 2004 to August 2016. Hormone replacement therapy including human chorionic gonadotropin 5.000-10.000 IU weekly and human menopausal gonadotropin 150-225 IU weekly were given before ART cycles. ART cycles were planned when hormone levels were in eugonadotropic and/or sperm was observed in the ejaculate. ART cycles were divided into two groups according to sperm source as ejaculated (n¼94) and testicular spermatozoa used (n¼25). Total number of retrieved and metaphase II oocytes, fertilization, clinical pregnancy and life birth rates were compared between two groups. Additionaly, ART cycles were also evaluated in fresh (n¼91) and frozen embryo (n¼28) cycles.
RESULTS: Male mean age and duration of infertility were 35.8AE5.64 and 6.1AE4.16 years, respectively. While ejaculated sperm was used in 94 (79%) cycles, testicular sperm was used in 25 (21%) cycles with persistent azoospermia despite hormonal treatment. Micro TeSe was performed on 16 patients (13.4%), and sperm was found in 13 of them. Therefore, the sperm retrieval rate with micro TeSe was 81.3% in hypogonadotropic hypogonadism. Compared parameters were given in Table 1 . While there was observed statistically significant difference in clinical pregnancy rate between two groups according to sperm source (p¼0.017); there were not observed any statistical differences among other compared parameters. Additionally, the ART outcomes were evaluated in fresh and frozen embryo transfered ART cycles. In fresh and frozen embryo cycles, pregnancy rate was 48.4% and 42.9% and life birth rate was 34.1% and 25%, respectively. There were not observed statistical differences between these parameters (p>0.05).
CONCLUSIONS: Patients with hypogonadotropic hypogonadism have high fertilization and pregnancy rates in both of fresh and frozen ART cycles. Although sperm retrieval rate is higher with micro TeSe, ejaculated spermatozoa can be used effectively for ART.
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